文献速递肾癌与肾肿瘤

根治性肾切除术中肾上腺切除:加拿大肾癌信息系统现代队列的发病率与肿瘤学结局

Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort.
PubMed 文献 · Urology · 2021-06-12

基于加拿大肾癌信息系统2011年1月至2020年2月14家中心的前瞻性队列,2759例接受根治性肾切除术的患者中831例(30.1%)同期行肾上腺切除,病理肾上腺受累102例(总体3.7%,肾上腺切除者中12.3%)。结论:肾上腺切除不改善肿瘤学结局,应限于影像学或术中肾上腺受累者。

要点

  • 现代实践中根治性肾切除术同期肾上腺切除比例为30.1%。
  • 病理肾上腺受累总体仅3.7%,在肾上腺切除患者中为12.3%。
  • 肾上腺切除与更高复发风险相关(HR 1.23),生存无差异。

核心结论

  • 肾上腺切除与更好的复发或生存结局无关,应仅用于影像学或术中肾上腺受累的患者。

研究设计与样本

  • 加拿大肾癌信息系统(CKCis)前瞻性队列,纳入2011年1月至2020年2月14家加拿大中心接受根治性肾切除术的患者。
  • 排除非肾细胞癌组织学、多发性肿瘤、对侧肿瘤、转移性疾病或既往肾细胞癌病史者,最终分析2759例。

主要发现

  • 2759例中831例(30.1%)同期行肾上腺切除,病理肾上腺受累102例(总体3.7%,肾上腺切除者中12.3%)。
  • 中位随访21.6个月(四分位距7.0-46.5)。
  • 肾上腺切除组静脉瘤栓比例更高(30.3% vs 9.6%,P<.0001),pT3/4比例更高(71.1% vs 43.4%,P<.0001),淋巴结转移更多(17.6% vs 10.7%,P=.0035),Fuhrman 3/4级比例更高(71.4% vs 56.2%,P<.0001),透明细胞组织学比例更高(79.3% vs 74.5%,P=.0074)。
  • 肾上腺切除组复发风险更高(HR 1.23;95%CI 1.04-1.47;P=.019),生存无差异(HR 1.09,95%CI 0.86-1.38,P=.48)。

临床怎么用

  • 不推荐在根治性肾切除术中常规行同侧肾上腺切除。
  • 肾上腺切除应保留给影像学提示肾上腺受累和/或术中发现肾上腺受累的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize proportion of patients receiving adrenalectomy, adrenal involvement prevalence and oncologic outcomes of routine adrenalectomy in contemporary practice. Ipsilateral adrenalectomy was once standard during radical nephrectomy. However, benefit of routine adrenalectomy has been questioned because adrenal involvement of renal cell carcinoma (RCC) is low. METHODS: All patients receiving radical nephrectomy in the Canadian Kidney Cancer information system, a collaborative prospective cohort populated by 14 major Canadian centers, between January 2011 to February 2020 were included. Patients were excluded if they had non-RCC histology, multiple tumors, contralateral tumors, metastatic disease or previous history of RCC. Patient demographic, clinical, and surgical information were summarized and compared. Cox-proportional hazards was used for multivariable analysis. RESULTS: During study period, 2759 patients received radical nephrectomy, of these, 831(30.1%) had concomitant adrenalectomy. Pathological adrenal involvement was identified in 102 (3.7%overall; 12.3%of adrenalectomy). Median follow-up was 21.6months (Interquartile range 7.0-46.5). Patients with adrenalectomy had higher venous tumor thrombus (30.3% vs 9.6%; P <.0001), higher T stage (71.1% vs 43.4% pT3/4; P <.0001), lymph node metastases (17.6% vs 10.7%; P = .0035), Fuhrman grades (71.4% of Fuhrman grades 3/4 vs 56.2%; P <.0001) and increased proportion of clear cell histology (79.3% vs 74.5%; P = .0074) compared to the no adrenalectomy group. Adrenalectomy patients had higher risk of recurrence (HR 1.23; 95% CI 1.04-1.47; P = .019) and no difference in survival (HR 1.09, 95% CI 0.86-1.38, P = .48). CONCLUSION: Adrenalectomy is not associated with better oncological outcome of recurrence/survival. Adrenalectomy should be reserved for patients with radiographic adrenal involvement and/or intra-operative adrenal involvement.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lavi A, Breau RH, Mallick R, et al. Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology. 2021. PMID: 34129893. doi:10.1016/j.urology.2021.05.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。